2022 January 06
1.
The association between deprivation and the access to disease modifying therapies for multiple sclerosis: An England wide community-based study in the UK MS Register. Das J, Rog DJ, Middleton R, Rodgers JW, Fry R, Nicholas R.
Mult Scler Relat Disord. 2021 Dec 26;57:103474. doi: 10.1016/j.msard.2021.103474. Online ahead of print.
PMID: 34986456
2.
Prevalence of trigeminal neuralgia in multiple sclerosis: A systematic review and meta-analysis. Houshi S, Tavallaei MJ, Barzegar M, Afshari-Safavi A, Vaheb S, Mirmosayyeb O, Shaygannejad V.
Mult Scler Relat Disord. 2021 Dec 29;57:103472. doi: 10.1016/j.msard.2021.103472. Online ahead of print.
PMID: 34986455 Review.
3.
CXCL4 drives fibrosis by promoting several key cellular and molecular processes. Affandi AJ, Carvalheiro T, Ottria A, de Haan JJ, Brans MAD, Brandt MM, Tieland RG, Lopes AP, Fernández BM, Bekker CPJ, van der Linden M, Zimmermann M, Giovannone B, Wichers CGK, Garcia S, de Kok M, Stifano G, Xu YJ, Kowalska MA, Waasdorp M, Cheng C, Gibbs S, de Jager SCA, van Roon JAG, Radstake TRDJ, Marut W.
Cell Rep. 2022 Jan 4;38(1):110189. doi: 10.1016/j.celrep.2021.110189.
PMID: 34986347
4.
Ponesimod inhibits astrocyte-mediated neuroinflammation and protects against cingulum demyelination via S1P1 -selective modulation. Kihara Y, Jonnalagadda D, Zhu Y, Ray M, Ngo T, Palmer C, Rivera R, Chun J.
FASEB J. 2022 Feb;36(2):e22132. doi: 10.1096/fj.202101531R.
PMID: 34986275
5.
DICAM promotes TH17 lymphocyte trafficking across the blood-brain barrier during autoimmune neuroinflammation. Charabati M, Grasmuck C, Ghannam S, Bourbonnière L, Fournier AP, Lécuyer MA, Tastet O, Kebir H, Rébillard RM, Hoornaert C, Gowing E, Larouche S, Fortin O, Pittet C, Filali-Mouhim A, Lahav B, Moumdjian R, Bouthillier A, Girard M, Duquette P, Cayrol R, Peelen E, Quintana FJ, Antel JP, Flügel A, Larochelle C, Arbour N, Zandee S, Prat A.
Sci Transl Med. 2022 Jan 5;14(626):eabj0473. doi: 10.1126/scitranslmed.abj0473. Epub 2022 Jan 5.
PMID: 34985970
6.
Patient-Reported Outcome Severity and Emotional Salience Network Disruption in Multiple Sclerosis. Fuchs TA, Vaughn CB, Benedict RHB, Weinstock-Guttman B, Bergsland N, Jakimovski D, Ramasamy D, Zivadinov R, Dwyer MG.
Brain Imaging Behav. 2022 Jan 5. doi: 10.1007/s11682-021-00614-5. Online ahead of print.
PMID: 34985619
7.
Long non-coding RNA ACTA2-AS1 inhibits the cisplatin resistance of non-small cell lung cancer cells through inhibiting autophagy by suppressing TSC2. Liu X, Zhang X, Du S.
Cell Cycle. 2022 Jan 5:1-11. doi: 10.1080/15384101.2021.2020433. Online ahead of print.
PMID: 34985374
8.
A Comprehensive Review on the Role of the Gut Microbiome in Human Neurological Disorders. Sorboni SG, Moghaddam HS, Jafarzadeh-Esfehani R, Soleimanpour S.
Clin Microbiol Rev. 2022 Jan 5:e0033820. doi: 10.1128/CMR.00338-20. Online ahead of print.
PMID: 34985325
9.
The reliability of gait parameters captured via instrumented walkways: a systematic review and meta-analysis. Parati M, Ambrosini E, DE Maria B, Gallotta M, Dalla Vecchia LA, Ferriero G, Ferrante S.
Eur J Phys Rehabil Med. 2022 Jan 5. doi: 10.23736/S1973-9087.22.07037-X. Online ahead of print.
PMID: 34985239
10.
Constraint-induced movement therapy for upper limb rehabilitation in multiple sclerosis. Grange E, Ferriero G, Dileo L, Solaro C.
Eur J Phys Rehabil Med. 2022 Jan 5. doi: 10.23736/S1973-9087.22.07025-3. Online ahead of print.
PMID: 34985238 No abstract available.
11.
Liraglutide attenuate central nervous inflammation and demyelination through AMPK and pyroptosis-related NLRP3 pathway. Song S, Guo R, Mehmood A, Zhang L, Yin B, Yuan C, Zhang H, Guo L, Li B.
CNS Neurosci Ther. 2022 Jan 5. doi: 10.1111/cns.13791. Online ahead of print.
PMID: 34985189
12.
Susac’s syndrome diagnostic difficulties – the neurological point of view. Fonderska P, Tomalka-Kochanowska J, Kochanowski J, Domitrz I.
Neurol Neurochir Pol. 2022 Jan 5. doi: 10.5603/PJNNS.a2021.0082. Online ahead of print.
PMID: 34985117
13.
Results from a multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin injection for multiple sclerosis relapse that did not adequately respond to corticosteroids. Wynn D, Goldstick L, Bauer W, Zhao E, Tarau E, Cohen JA, Robertson D, Miller A.
CNS Neurosci Ther. 2022 Jan 4. doi: 10.1111/cns.13789. Online ahead of print.
PMID: 34984839
14.
Reduction in cognitive processing speed surrounding multiple sclerosis relapse. McKay KA, Bedri SK, Manouchehrinia A, Stawiarz L, Olsson T, Hillert J, Fink K.
Ann Neurol. 2022 Jan 4. doi: 10.1002/ana.26301. Online ahead of print.
PMID: 34984719
15.
Predominant monomorphism of the RIT2 and GPM6B exceptionally long GA blocks in human and enriched divergent alleles in the disease compartment. Khamse S, Arabfard M, Salesi M, Behmard E, Jafarian Z, Afshar H, Khazaei M, Ohadi M.
Genetica. 2022 Jan 5. doi: 10.1007/s10709-021-00143-5. Online ahead of print.
PMID: 34984576
16.
Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies. Prosperini L, Tortorella C, Haggiag S, Ruggieri S, Galgani S, Gasperini C.
J Neurol. 2022 Jan 4. doi: 10.1007/s00415-021-10951-6. Online ahead of print.
PMID: 34984514
17.
Hyponatremia: A Tip of the Iceberg in the Late Diagnosis of Tuberous Sclerosis Associated With Lymphangioleiomyomatosis. Paiva D, De Carvalho A, Campos AL, Gonçalves F, Silva C, Miranda O, Barbosa S, Cotter J.
Cureus. 2021 Dec 3;13(12):e20131. doi: 10.7759/cureus.20131. eCollection 2021 Dec.
PMID: 34984158 Free PMC article.
2022 January 05
1.
Intelligibility Across a Reading Passage: The Effect of Dysarthria and Cued Speaking Styles. van Brenk F, Stipancic K, Kain A, Tjaden K.
Am J Speech Lang Pathol. 2022 Jan 4:1-19. doi: 10.1044/2021_AJSLP-21-00151. Online ahead of print.
PMID: 34982941
2.
Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany. Ziemssen T, Lang M, Schmidt S, Albrecht H, Klotz L, Haas J, Lassek C, Lang S, Winkelmann VE, Ettle B, Schulze-Topphoff U; PANGAEA study group.
J Neurol. 2022 Jan 4. doi: 10.1007/s00415-021-10931-w. Online ahead of print.
PMID: 34982201
3.
Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study. Bigaut K, Kremer L, Fabacher T, Ahle G, Goudot M, Fleury M, Gaultier C, Courtois S, Collongues N, de Seze J.
J Neurol. 2022 Jan 4. doi: 10.1007/s00415-021-10950-7. Online ahead of print.
PMID: 34982200
4.
Advances in the use of stem cell transplants in the treatment of multiple sclerosis. Thomas R, Wynford-Thomas R, Robertson NP.
J Neurol. 2022 Jan 4. doi: 10.1007/s00415-021-10927-6. Online ahead of print.
PMID: 34982199 No abstract available.
5.
Targeting neuroinflammation by intranasal delivery of nanoparticles in neurological diseases: a comprehensive review. Moradi F, Dashti N.
Naunyn Schmiedebergs Arch Pharmacol. 2022 Jan 4. doi: 10.1007/s00210-021-02196-x. Online ahead of print.
PMID: 34982185 Review.
6.
Brain Pathology in Multiple Sclerosis with High-Field-Strength MR Spectroscopic Imaging. Barker PB.
Radiology. 2022 Jan 4:212026. doi: 10.1148/radiol.212026. Online ahead of print.
PMID: 34981980 No abstract available.
7.
Extensive Brain Pathologic Alterations Detected with 7.0-T MR Spectroscopic Imaging Associated with Disability in Multiple Sclerosis. Heckova E, Dal-Bianco A, Strasser B, Hangel GJ, Lipka A, Motyka S, Hingerl L, Rommer PS, Berger T, Hnilicová P, Kantorová E, Leutmezer F, Kurča E, Gruber S, Trattnig S, Bogner W.
Radiology. 2022 Jan 4:210614. doi: 10.1148/radiol.210614. Online ahead of print.
PMID: 34981978
8.
Economic burden of multiple sclerosis: a cross-sectional study in Iran. Rezaee M, Keshavarz K, Izadi S, Jafari A, Ravangard R.
Health Econ Rev. 2022 Jan 3;12(1):2. doi: 10.1186/s13561-021-00350-y.
PMID: 34981265
9.
Analysis of Micro-RNA-144 Expression Profile in Patients with Multiple Sclerosis in Comparison with Healthy Individuals. Roshani F, Delavar Kasmaee H, Falahati K, Arabzade G, Sohan Forooshan Moghadam A, Sanati MH.
Rep Biochem Mol Biol. 2021 Oct;10(3):396-401. doi: 10.52547/rbmb.10.3.396.
PMID: 34981016 Free PMC article.
10.
Acute Disseminated Encephalomyelitis: Psychiatric Presentation of a Rare Diagnosis. Baral A, Gyawali R, Upreti D, Mishra A, Gupta AK.
Innov Clin Neurosci. 2021 Jul-Sep;18(7-9):44-46.
PMID: 34980993 Free PMC article.
11.
Improving Healthcare Professional Psychological Well-being in Neurorehabilitation: An Exploratory Study Focusing on Work Stress. Maggio MG, Manuli A, Andaloro A, Chirieleison A, La Rosa G, Sciarrone F, Trinchera A, Calabrò RS.
Innov Clin Neurosci. 2021 Jul-Sep;18(7-9):21-28.
PMID: 34980990 Free PMC article.
12.
Mendelian randomization study updates the effect of 25-hydroxyvitamin D levels on the risk of multiple sclerosis. Wang R.
J Transl Med. 2022 Jan 3;20(1):3. doi: 10.1186/s12967-021-03205-6.
PMID: 34980161
13.
Acute to Subacute Spinal Cord Infarction Mimicking Acute Multiple Sclerosis: Usefulness of Diffusion-Weighted MRI for Diagnosis. Lee KY, Khil EK, Jo SW, Jang MU, Choi JA, Lee MS.
Curr Med Imaging. 2022 Jan 3. doi: 10.2174/1573405618666220103105910. Online ahead of print.
PMID: 34979892
14.
The Effect of the Activation of the Core Muscles on Tremor in a Patient with Multiple Sclerosis. Usta A, Salcı Y, Yildiz FG, Çakmaklı GY, Armutlu K.
Neurol India. 2021 Nov-Dec;69(6):1798-1801. doi: 10.4103/0028-3886.333519.
PMID: 34979692
15.
Multiple Sclerosis-Minimizing Errors in Radiological Diagnosis. Boski N, Gulati V, Raj R, Gulati P.
Neurol India. 2021 Nov-Dec;69(6):1539-1546. doi: 10.4103/0028-3886.333497.
PMID: 34979638 Review.
16.
Therapeutic Application of rTMS in Atypical Parkinsonian Disorders. Petsani C, Aloizou AM, Siokas V, Messinis L, Peristeri E, Bakirtzis C, Nasios G, Dardiotis E.
Behav Neurol. 2021 Dec 23;2021:3419907. doi: 10.1155/2021/3419907. eCollection 2021.
PMID: 34976231 Free PMC article. Review.
17.
Myelin-associated oligodendrocyte basic protein rs616147 polymorphism as a risk factor for Parkinson’s disease. Siokas V, Aloizou AM, Liampas I, Bakirtzis C, Tsouris Z, Sgantzos M, Liakos P, Bogdanos DP, Hadjigeorgiou GM, Dardiotis E.
Acta Neurol Scand. 2022 Feb;145(2):223-228. doi: 10.1111/ane.13538. Epub 2021 Oct 25.
PMID: 34694630
18.
NK Cell Patterns in Idiopathic Inflammatory Myopathies with Pulmonary Affection. Pawlitzki M, Nelke C, Rolfes L, Hasseli R, Tomaras S, Feist E, Schänzer A, Räuber S, Regner L, Preuße C, Allenbach Y, Benveniste O, Wiendl H, Stenzel W, Meuth SG, Ruck T.
Cells. 2021 Sep 27;10(10):2551. doi: 10.3390/cells10102551.
PMID: 34685530 Free PMC article.
19.
MRI, Big Data, and Artificial Intelligence: Rewards vs Risks. Ontaneda D, Ross LA, Hohlfeld R.
Neurology. 2021 Nov 23;97(21):975-976. doi: 10.1212/WNL.0000000000012883. Epub 2021 Oct 4.
PMID: 34607921 No abstract available.
20.
Inflammation as a Target for Epilepsy Therapy: The Case of Natalizumab. Miller JW.
Neurology. 2021 Nov 2;97(18):845-846. doi: 10.1212/WNL.0000000000012768. Epub 2021 Sep 14.
PMID: 34521688 No abstract available.
21.
Diana Pineda. Marwaha S.
CMAJ. 2021 Jul 12;193(27):E1061. doi: 10.1503/cmaj.210988.
PMID: 34253552 Free PMC article. No abstract available.
22.
Présence de pseudokystes gélatineux en contexte de cryptococcose du système nerveux central. Ding JZ, Torres C.
CMAJ. 2021 Jul 5;193(26):E1029-E1030. doi: 10.1503/cmaj.201547-f.
PMID: 34226273 Free PMC article. French. No abstract available.